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Campath-1H (alemtuzumab) is used during conditioning to
prevent graft-versus-host disease and improve engraftment.
Pharmacokinetic data have shown that a commonly employed
dose of alemtuzumab (20 mg/day x 5, total dose 100 mg) results
in potentially lympholytic alemtuzumab levels for 50 days
post-transplant. Delayed alemtuzumab clearance might con-
tribute to increased incidence of viral infections. We there-
fore studied the effect of a reduced dose of alemtuzumab (20
mg/day x 2, total dose 40 mg) on CMV reactivation. Nine
patients (6 male, 3 female; median age 41 yrs, range 22-55 yrs)
underwent allogeneic stem cell transplantation (7 MUD, 2
MRD) for a variety of hematologic malignancies after condi-
tioning with thiotepa/TBI/alemtuzumab (7 patients) or ﬂudara-
bine/melphalan/alemtuzumab (2 patients). Five patients were at
risk for CMV reactivation (patient or donor CMV seropositive).
Alemtuzumab was administered IV on day -5 and -1 prior to
stem cell infusion. CMV reactivation was checked weekly by
CMV pp65 antigenemia testing in at-risk patients. All patients
received leukocyte depleted blood products (third generation
ﬁlter). All patients engrafted. Four out of ﬁve patients at-risk
(80%) developed CMV reactivation at a median of 28 (range
17-32) days post-transplant. No CMV infection occurred in
low-risk patients (patient and donor both CMV seronegative).
CMV reactivation was treated with IV ganciclovir induction for
a minimum of two weeks, followed by IV or PO (val)ganciclovir
maintenance. Two patients had a febrile illness at the time of
CMV reactivation, however no evidence of CMV disease was
found on imaging studies and/or biopsies. Repeated reactivation
occurred in two patients, and was responsive to retreatment
with ganciclovir or foscarnet with the addition of IVIG. No
patient died from CMV related complications. We conclude
that early CMV reactivation remains a frequently encountered
problem after conditioning regimens containing reduced dose
alemtuzumab. CMV prophylaxis should be considered in at-risk
patients.
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SEX STREOID ABLATION THERAPY RESTORES THYMIC FUNCTION AND
ENHANCES HEMOPOIESIS AND LYMPHOPOIESIS FOLLOWING ALLOGE-
NEIC AND AUTOLOGOUS STEM CELL TRANSPLANTATION
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Opportunistic infection, morbidity and mortality are common
following HSC transplantation because of the failure to regen-
erate an adequate immune system. This is due to the severe sex
steroid induced thymic atrophy that occurs with age. Using
surgical or temporary chemical (LHRH/GnRH) castration we
have shown that blocking sex steroids profoundly enhances
thymus function and immune capacity in adult and aged mice.
This involved triggering proliferation of the early thymocyte
precursors, reduction of apoptotic cells and restored thymic
architecture. In addition, in mouse BMT models there was a
signiﬁcant enhancement of BM function and levels therein of
HSC in castrated mice. The HSC were readily incorporated
into the marked regeneration of the thymus. Thus, sex steroid
ablation enhances immune regeneration both at the HSC (BM)
and intrathymic levels. We then examined prostate cancer pa-
tients undergoing routine sex steroid ablation therapy. They
had a signiﬁcant increase in blood T lymphocytes (importantly
CD4 naive TREC) and NK cells, by 4-months post-treat-
ment. This lead to clinical trials using an LHRH agonist to
ablate sex steroids in patients receiving allogeneic or autologous
peripheral blood HSC transplantation (PBST). Compared to
control patients (no LHRH-A treatment), there was ﬁrstly a
signiﬁcantly decreased time to engraftment with both autolo-
gous and allogeneic PBST LHRH-A recipients showing signif-
icant increases in neutrophil counts, total WBC and lymphocyte
counts within the ﬁrst month post-transplant compared to con-
trols. In addition there was a signiﬁcant increase in CD34
stem cell numbers and NK cells in the autologous transplant
recipients who had received the LHRH-A. Importantly the
allogeneic recipients in particular showed an increase in total
and naive (CD45RACD62LCD45RO-; TREC)T cell
numbers in the blood at all time-points post-transplant com-
pared to controls. Patients receiving the LHRH-A treatment
also demonstrated a signiﬁcantly increased in vitro proliferative
responsiveness to TCR stimulation and Tetanus Toxin. These
studies set a fundamentally new approach for the treatment of
many clinically based T-cell disorders.
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BONE MARROW ANGIOGENESIS DECREASES AFTER STEM CELL TRANS-
PLANTATION FOR TREATMENT OF LEUKEMIA
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K.1, Ghavamzadeh, A.1 1. Dr Shariatii Hospital, Tehran, Tehran,
Islamic Republic of Iran; 2. Dr Shariatii Hospital, Tehran, Tehran,
Islamic Republic of Iran.
Background: Bone marrow transplantation is an important
mode of therapy in adult leukemia pateinets. Increased bone
marrow angiogenesis is shown to participate in the progression
of leukemia by direct stimulatory effect of the cytokine secreted
by endothelial cells on the proliferation of leukemia cells, thus
the bone marrow angiogenesis might be a contributory factor in
relapse and also response to therapy. Previous studies have
shown that bone marrow angiogenesis might decrease after stem
cell transplantation in multiple myeloma patients. Aims: To
study whether bone marrow transplantation for the treatment of
leukemia affects the bone marrow vascular density and to clarify
its clinical signiﬁcance. Materials and methods: Pre- and post-
transplant (30 days after transplantation) bone marrow biopsy
samples of 13 patients (3 autologous, 10 allogenic) including 9
AML and 4 ALL patients were evaluated using immunohisto-
chemical staining for vWF. All the vessels in the bone marrow
biopsy core were counted and results were corrected for the
bone marrow biopsy length .The correlation between the de-
gree of decrease in angiogenesis and relapse and Graft-Versus-
Host-Disease was also studied. Results: The bone marrow
angiogenesis was signiﬁcantly decreased after one month of
chemotherapy (Mean pre-transplant vascular number  5.6/mm
/-0.9 SEM, Mean post-transplant vascular number  1.6/mm,
/- 0.26 SEM, P  0.001).There was no correlation between
the degree of angiogenesis and bone marrow cellularity (which
returned to near -normal levels at the time of post-transplant
biopsy).The changes in bone marrow vascular density also did
not correlate with the type of transplant, relapse or the occur-
rence of Graft-Versus-Host-Disease. Discussion: A signiﬁcant
and robust decrease in the bone marrow angiogenesis after stem
cell transplantation for leukemia was shown. This might be a
contributing factor in excellent results of bone marrow trans-
plantation for leukemia by decreasing proliferation stimula-
tory cytokines from the endothelial cells.The lack of correla-
tion between relapse and decrease in bone marrow density
might be attributable to the multifactorial nature of relapse in
leukemia.
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AML TRANSPLANTATION: AUTOLOGOUS VS ALLOGENEIC
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